SynthesisFrontiers in pharmacology2025
Protective effects of curcumin on epileptic rodent models by alleviating oxidative stress and inflammation: a meta-analysis and mechanism exploration.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Kolaviron offers significant neuroprotection on potassium dichromate-induced neurobehavioral, biochemical, histopathological, and immunohistochemical changes in rats.IBRO neuroscience reports · 2026Article
- Anti-Inflammatory and Antioxidant Strategies in Epilepsy: From Molecular Mechanisms to Threshold Management.International journal of molecular sciences · 2026Review
- Curcumin Attenuates Glyphosate-Induced Mammary Toxicity via Suppression of ER Stress and the TNFα/MAPK/STAT3 Axis.Antioxidants (Basel, Switzerland) · 2026Article
- Protective Effect of Aromatic Plant Essential Oil Administration on Brain Tissue of PTZ-Treated and Non-Treated Mice.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study is to systematically evaluate the therapeutic effect of curcumin on rodent epilepsy models through a meta-analysis of multiple animal experiments. It will also explore its potential mechanism of anti-oxidative stress and anti-inflammation to provide a theoretical basis for the application of curcumin in the clinical treatment of epilepsy. Methods: A total of 23 eligible animal studies were identified by searching eight databases (up to March 2025), including PubMed, Embase, Web of Science, Cochrane Library, and CNKI, Wan Fang, VIP, CBM. SYRCLE's risk of bias tool was used to assess the quality of the literature, and Meta-analysis was performed using Review Manager 5.4 and Stata 18 software. Primary outcome measures included epilepsy latency, Morris water maze escape latency, oxidative stress markers (MDA, GSH, SOD), inflammatory factors (IL-1β, TNF-α), and Glial fibrillary acidic protein (GFAP). Results: Meta-analysis showed that the curcumin intervention group significantly extended the epilepsy latency (SMD = 1.85, 95% CI = 1.05-2.64, P < 0.00001) and shortened the water maze escape latency (SMD = -1.69, 95% CI = -2.23-1.16, P < 0.00001). In terms of antioxidant indicators, curcumin significantly decreased MDA levels (SMD = -3.50, P < 0.00001) and increased GSH (SMD = 2.87, P < 0.00001) and SOD (SMD = 2.42, P < 0.00001). The anti-inflammatory results showed that the levels of IL-1β (SMD = -1.73, P = 0.04) and TNF-α (SMD = -1.65, P < 0.00001) were significantly decreased, and the levels of GFAP-positive cells were decreased (SMD = -1.72, P = 0.05). Subgroup analysis showed that medium and high doses (100-299 mg/kg and ≥300 mg/kg) of curcumin were more stable, but the low dose group (<100 mg/kg) did not conduct in-depth analysis due to insufficient sample size of individual indicators. Sensitivity analysis and funnel plots suggest robust results, but some publication bias exists. Conclusion: Curcumin can effectively improve epileptic seizures and cognitive dysfunction in epileptic rodents through the dual mechanisms of antioxidative stress (inhibiting lipid peroxidation and enhancing antioxidant enzyme activity) and anti-inflammatory (reducing the release of pro-inflammatory factors and inhibiting glial cell activation). However, species differences and potential publication bias have certain effects on the results, and high-quality clinical studies can be carried out in the future to verify their clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.